Form 4: Arbutus Biopharma Director Anuj Hasija Granted Stock Options

Director Anuj Hasija of Arbutus Biopharma Corp. receives stock options exercisable for 157,600 common shares.

Summary

• Anuj Hasija, a director of Arbutus Biopharma Corp, was granted stock options on March 18, 2025.
• The options are exercisable for 157,600 common shares at a price of $3.20 per share.
• The options vest over a three-year period, with one-third of the shares vesting annually on the anniversary of the grant date, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing performance and value creation.

Risks

• The value of the stock options is dependent on the future performance of Arbutus Biopharma's stock price, which is subject to market risks and company-specific factors.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the biopharmaceutical industry to incentivize executives and align their interests with those of shareholders. The size and vesting schedule of the grant are typical for director-level compensation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Gilead Sciences, Amgen, and Vertex Pharmaceuticals also utilize stock options to incentivize their directors and officers.
• The vesting schedule of three years is a common practice to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to increase shareholder value.
• Employees may see it as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Arbutus Biopharma, director, ABUS, equity, Anuj Hasija, Form 4